The following is a summary of the Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Dare reported Q1 2024 general and administrative expenses of approximately $2.7 million.

• R&D expenses were approximately $3.3 million—a 34% decrease compared to Q1 2023.

• The Company's loss for the quarter was approximately $6.8 million.

• Dare ended the quarter with $3.6 million in cash and equivalents.

• Dare secured a non-dilutive strategic royalty financing of $22 million and received total grant funding of approximately $1.8 million.

Business Progress:

• Dare's product, XACIATO, is now available via prescription nationwide for treating bacterial vaginosis.

• The Company is preparing for Phase 3 clinical trials of Sildenafil Cream 3.6% and Ovaprene.

• They completed an end-of-Phase 2 meeting with the FDA regarding Sildenafil Cream.

• Technological proof-of-concept for DARE-LARC1, Dare's pre-clinical candidate, was announced.

• The company continues collaborations with major corporations including Organon for XACIATO and Bayer for Ovaprene.

• Dare is planning to initiate a Sildenafil Phase 3 trial in early 2024, hopeful of it being the first Phase 3 study for female sexual arousal disorder.

• The company is also progressing with DARE-LARC, a technology similar to 'Nexplanon', and is developing therapies for menopausal vasomotor symptoms and sexual pain.

• Dare aims to position women's health at the forefront of innovation.

More details: Dare Bioscience IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.